Skip to main content

Department of Pharmacology Archives

The yin and yang of COX-2

Oct. 2, 2015—New findings add to the understanding of how the enzyme COX-2 works, which is critical to the development of COX-2-targeted anti-inflammatory drugs.

Read more


Collaboration seeks to develop new therapies for bone, other diseases

Oct. 1, 2015—La Jolla Pharmaceutical Co. and Vanderbilt University have signed a research and license agreement covering Vanderbilt’s research program and intellectual property rights related to compounds that block bone morphogenetic protein (BMP) type-I receptors. The compounds have therapeutic potential in a broad range of diseases, including rare genetic disorders.

Read more


VUMC study shifts thinking on how bone fractures heal

Aug. 13, 2015—New findings show that fibrin, a protein that was thought to play a key role in fracture healing, is not required, shifting understanding of how fractures heal.

Read more


Bridging the antibiotic gap

Aug. 7, 2015—Vanderbilt researchers have discovered how certain molecules with antibiotic properties are synthesized, findings that could lead to new drugs that overcome the increased antibiotic resistance in bacteria.

Read more


How to trick a wily virus

Jul. 24, 2015—Vanderbilt investigators have discovered how human antibodies induced during testing of an experimental “bird flu” vaccine kill the virus.

Read more


Lit up COX-2 cancer probe

Jun. 17, 2015—A new imaging probe developed by Vanderbilt investigators enhances tumor visibility and has broad applications in diagnosing and monitoring patients with cancer.

Read more


New strategy to combat HIV

Jun. 12, 2015—Inhibitors of the enzyme phospholipase D1 suppress the replication of HIV-1, Vanderbilt investigators have discovered.

Read more


Findings reveal new target in quest to ease schizophrenia

May. 7, 2015—Vanderbilt University researchers have uncovered a surprising finding that could lead to the development of new, more effective therapies for schizophrenia, which affects more than 2 million Americans.

Read more


Neurofibromin fine-tunes bone growth

May. 6, 2015—The protein neurofibromin acts as a brake in a signaling pathway that is important in bone development, Vanderbilt researchers have discovered.

Read more


Lecture explores efforts to move pharmacogenetics into the clinic

Apr. 23, 2015—Preemptive genotyping: It sounds like a surprise attack, and it is.

Read more


Cancer signaling pathway blocker

Apr. 3, 2015—Researchers at Vanderbilt University have discovered a new way to inhibit Hedgehog (Hh) signaling, an important regulatory pathway for vertebrate development – and cancer.

Read more


Pharmacogenomics expert set for Wilkinson Lecture

Apr. 2, 2015—Mary Relling, Pharm.D., chair of the Department of Pharmaceutical Sciences at St. Jude Children’s Research Hospital in Memphis, will deliver this year’s Grant R. Wilkinson Distinguished Lecture in Clinical Pharmacology on Thursday, April 9.

Read more


Upcoming Events

MORE EVENTS »